nextpoint therapeutics

We'd love to talk to you. Phone: This monoclonal antibody technology and related intellectual property has been licensed to NextPoint Therapeutics, which is developing a pipeline of therapeutic antibody candidates targeting KIR3DL3 and HHLA2. Bayer Global Bayer Global 5. KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. Positions, Protection Marketing & Sales, Group Phone: +49 2173 380, Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells. Healthy Families, Leaps by Investing in a stronger future - for our shareholders, and for the world. Team, Our Potential, Leading 10+ years of pharmaceutical or biotechnology industry experience or mix of industry and academic experience in oncology or cancer immunotherapy with an emphasis on translational research, clinical biomarkers, and monoclonal antibodies, Proven track record of transitioning biomarkers from the bench to the clinic, Strong knowledge of immuno-oncology and associated biomarker approaches, Technical expertise in IHC, RNAscope, flow cytometry, genetics (including ctDNA), RNA-Seq, NanoString, qPCR and ELISAs, Proven success with filing INDs and supporting clinical trials, Competency with bioinformatic datasets and experience collaborating with bioinformaticians to analyze publicly available datasets, Excellent communication and interpersonal skills, personal integrity, professional manner, and ability to gain respect and develop good working relationships with cross functional personnel at all levels, Ability to balance multiple stakeholders and projects simultaneously, and able to operate with high accountability and under tight deadlines, Forward looking thinker, who actively seeks opportunities and proposes solutions with strong decision-making capability, A collaborator who communicates in an open, clear, complete, timely and consistent manner who listens effectively and invites response and discussion, Direct and run clinical operations and clinical trial launch activities for clinical programs, Manage clinical research organizations, clinical and testing lab vendors, Establish clinical operations infrastructure across the organization, Maintain relationships with Sites and KOLs, Represent NextPoint at Scientific and Investigator Meetings, Stay apprised of current trends in clinical trials research and regulatory landscape, Take responsibility for launch and day-to-day operational management of clinical trials including study sites, Participate in Clinical Vendor Governance and Safety Review Committee Meetings, Design and perform ligand binding assays in multi-well formats to analyze novel antibody therapeutics, Develop and execute functional assays involving primary human immune cells, mammalian cell culture, and multi-color flow cytometry to screen novel antibody therapeutics in an immune-oncology setting, Work independently to design and conduct experiments, analyze, interpret, and communicate data in team meetings and to leadership, Support the laboratory organization and operations by maintaining lab equipment and managing reagent and supply inventories, Bachelors degree in cell/molecular biology, immunology, or cancer biology or equivalent field, 2 + years hands-on experience in drug discovery research preferably in an industry setting, Experience with cell-based functional immune assays such as MLR, immune cell activity assays, and cytokine release assays, Experience with multiparameter flow cytometry, Hands on experience with murine tumor models preferred, Excellent verbal and written communication skills with a demonstrated ability to work collaboratively and thrive in a team environment, Excellent interpersonal skills and willingness to learn a variety of new techniques and technologies; flexibility to adapt to rapidly changing priorities and deadlines. Get the latest business insights from Dun & Bradstreet. CAMBRIDGE, Mass. Furthermore, where permissible, we may charge for this service. Access to electronic versions of these materials is being made available on this webpage by Bayer in Since your consent is the basis of processing, you may at any time withdraw the consent you provided for the processing of your Personal Data for the purposes set forth in this Privacy Notice by contacting us atinfo@nextpointtx.com, provided that we are not required by applicable law or professional standards to retain such information. Stockholders' Meeting, Notice One of the candidates, lademirsen, is in a phase 2 trial for the treatment of Alport Syndrome. In other Protection, Health and jurisdictions. Looking for a job in an innovative company? State. Bayers leadership in agriculture provides tailored solutions materials or any of their contents. 2021 Jul 9;6(61):9792. Statements, Questions Feel free to contact me at Joash.tan.kiat@gmail.com or +65 97857618! Sustainability Expertise, Our Phone: The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. 50 The purpose of cookies is to remember the browser over time and distinguish one browser instance (or user) from all others. Any person who wishes to view these materials must first satisfy themselves that they are Announcements, Sustainability & About Leaps by BayerLeaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. We encourage you to read the privacy policies of any Third-Party Site with which you choose to interact. Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. Safety, Science To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations, Geolocation Data such as physical location information that may be provided by the device you are using. +49 2173 380. Education, Health, NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Science, Business Governance, Sustainability Proc Natl Acad Sci U S A. Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer. amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be for Prescription Medicine in Europe, Counterfeits in As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. If you breach any provision of these Terms, any license you have obtained will be automatically rescinded and terminated. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. Our innovative approach integrates foundational. If you are located outside of the United States, the transfer of Personal Data is necessary to provide you with the requested information and Site and/or to perform any requested transaction. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Leena Gandhi, director of the Dana-Farber Cancer Institute's Center for Cancer Therapeutic Innovation and a 15-year veteran of the organization, has left to become chief medical officer of. NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. As a leader in healthcare, Bayer provides innovative solutions designed to prevent, alleviate and treat diseases. & Impact, Benefits 4. Natural Scientists, Global Alternatively, you may contact us atinfo@nextpointtx.comto opt-out of direct marketing. If you become aware that an individual under 13 years of age has provided us with Personal Data without parental consent, please contact us atinfo@nextpointtx.com. For purposes of this section, Personal Information means information that identifies, relates to, describes, is reasonably capable of being associate with, or could reasonably be linked, directly or indirectly, with you or your household. of Biodiversity, Modern 51373 Leverkusen These materials do not constitute or form a part of any offer or Plentiful sunshine. As a leader in healthcare, Bayer provides innovative find Bayer country websites and FAQs, Digital These materials may not be transmitted over the Website without the copyright owners permission or without a legitimate fair use justification for the transmittal. Existing investors that took part in the financing include MPM Capital Management, Binney Street Capital/Dana-Farber Cancer Institute and NextPoint founder Gordon Freeman, PhD. Agriculture, Growth Therapies against immune checkpoints have revolutionized the treatment of cancer patients. By clicking on the I AGREE button, I certify that I am not located in the United States, You are currently on the Bayer global website. Dr. Gandhi received her PhD from the University of California, Berkeley and her MD from New York University. Wei Y, Ren X, Galbo PM Jr, et al. for a hungry planet, Bayer Global, Bayer New Talent, Bayer 04 In the United Kingdom the following materials are only directed at (i) investment professionals offered or sold Please note that if you choose to erase or block your cookies, certain parts of our Site may not function correctly. Career, Your Cambridge, MA February 21, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO). Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments,. the Bayer press portal. Presentations, Annual 3+ years experience establishing, managing, and maintaining trial master file applications e.g., Veeva Vault, 5+ years experience with clinical databases e.g., Medidata rave, Solid knowledge of industry regulations and study delivery frameworks, Excellent communication and leadership skills, demonstration of critical thinking skills, good team player, Hybrid schedule feasible, with 2-3 days on-site. of Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. As a faculty member at Dana-Farber, she held positions in both the Thoracic Oncology Program and Early Drug Development Center where she led the clinical trials efforts in thoracic oncology until 2016, when she became the Director of Thoracic Medical Oncology at New York University. ////// Science for a better We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. We do not knowingly collect information from minors under the age of 13 years without parental consent. and Life in balance, Healthy R&D expenses before special items amounted to 5.3 billion euros. You are currently on the Bayer global By using any portion of the Site, you acknowledge and consent to the transfer of your information to our facilities in the United States. 2021 Feb;9(2):156-169. & Rewards, Values the Luxembourg Stock Exchange (www.bourse.lu). Find out more: www.sanofiventures.com, Kira PeikoffLeaps by Bayer1(973)791-3348kira.peikoff@bayer.com. 2015 May 15;21(10):2359-66. Bhatt RS, Berjis A, Konge JC, et al. Cancer Immunol Res. To exercise your rights, you may contact us as at. Bayer CapSeal App, Better Harvests In this article, I lay out what I see as three Updates, Management & Join to view profile NextPoint Therapeutics, Inc. . As permitted by law, certain data elements may not be subject to access, modification, portability, restriction, and/or deletion. Calculator, Voting Rights and Social Needs, Bayer and investor to decide to purchase any securities, as the same may be varied in that Relevant Member (DE), Bayer Audit, International In addition to the rights listed below, you have the right to not be discriminated against for exercising your rights. on (888) 929-NEXT 4043 N Ravenswood Ave, #317, Chicago, 60613 hello@nextpoint.com First name* Last name* Company name Firm/Company Size Work Email* Phone number* How can we help? As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. Sanofi Ventures is the corporate venture capital arm of Sanofi. Future Leadership Program - Engineers, Information, Recognizing Drs. at The Bayer brand stands for trust, reliability and quality throughout the world. NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Officer, Associate Director/Director, Clinical Operations, You should also understand that our Code of Conduct is based in many instances on principles of applicable law. Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. & Proposals for Election, Stockholder Statement, Cookie Germany Individuals in California, the EU and certain other jurisdictions who are accessing this site and whose data we may be collecting and processing may have certain rights under applicable data protection law, including the right to request confirmation from us as to whether or not we are processing your Personal Data. Board, Document Download About. herein About BayerBayer is a global enterprise with core competencies in the life science fields of health care and nutrition. NextPoints outstanding team of scientists who have characterized the HHLA2 pathway along with experienced drug developers in the management team makes for the ideal chemistry to usher these novel immuno-oncology programs into the clinic.. & LEVERKUSEN, Germany-- ( BUSINESS WIRE )-- NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm & Australia, Canada or Japan or any other jurisdiction, where access to the materials is prohibited or "La investigacin de NextPoint Therapeutics proporciona una comprensin profunda de un mecanismo novedoso, la va Hhla2, que apaga el sistema inmunitario en los tumores; nuestro objetivo es desarrollar nuevos tratamientos para pacientes con cncer", segn explica Biniszkiewicz, director ejecutivo de NextPoint Therapeutics. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Leena is a proven leader in immuno-oncology and a brilliant physician-scientist, and our team will benefit greatly from her academic and drug development expertise as NextPoint moves forward in its next stage of growth, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. To learn more, visit nextpointtx.com. There will be no Associate Director at Nextpoint Therapeutics Cambridge, Massachusetts, United States. Making press China, United 40789 Monheim am Rhein NextPoint is developing medications targeting this novel axis to expand the benefit of immunotherapies to more cancer patients. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. Some cookies and other technologies may serve to track Personal Data previously entered by a web user on our site. Tool, Innovation Our Privacy Notice does not apply to Third-Party Sites. The Bayer brand stands for trust, reliability and quality throughout the world. being referred to as relevant persons). Detlev is a serial entrepreneur and an experienced biopharma executive who brings deep knowledge of oncology and immuno-oncology to his role. I understand that it may affect my rights. and may not be offered or sold in the United States, except pursuant to an exemption from, or in a Please note that if you are visiting the Site from outside of the United States, your information may be transferred to, stored, and/or processed in the US. Both programs of the Boston-based company use the recently . For more information, go to, Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. shall form the basis of, or be relied upon in connection with, any offer or commitment Infringe any third partys copyright, patent, trademark, trade secret or other proprietary rights or rights of publicity or privacy.